When it comes to pediatric use of Endo Pharmaceuticals Inc.’s Opana IR (oxymorphone immediate-release), no information in labeling is better than unhelpful or potentially misleading data, a US Food and Drug Administration panel said on 26 September.
Sixteen of 25 voting members of the pediatric and drug safety/risk management advisory committees voted against adding pediatric study data to labeling for Opana IR, believing that including such information would give a false sense of security
Advisory Committee Votes
-
No new safety signals were identified for OxyContin (oxycodone hydrochloride) extended-release tablets in the current pediatric safety review. FDA recommends continuing ongoing, routine, postmarket safety monitoring, along with completion of the postmarketing required studies by the sponsor. Does the committee agree
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?